LGR4 and colorectal carcinoma: For example, research has shown that when LGR4-mAb targets the Wnt signaling pathway in combination with chemotherapeutic drugs, it can downregulate the key ferroptosis inhibitor SLC7A11, thereby overcoming acquired resistance in CRC [52].